Clinical Trial Update: Effect of Autologous Cord Blood Mononuclear Cells for Treatment of Bronchopulmonary Dysplasia in Extremely Preterm Neonates [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating autologous cord blood mononuclear cells for treatment of bronchopulmonary dysplasia in extremely preterm neonates.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchopulmonary Dysplasia

Drugs mentioned

• Autologous cord blood mononuclear cells

Snippet

Sponsor: Guangdong Women and Children Hospital | Conditions: BPD | Phase 3 | Status: UNKNOWN